*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the prospectus dated June 26, 2026 (the "**Prospectus**") issued by Beijing Tong Ren Tang Healthcare Investment Co., Ltd. (北京同仁堂醫養投資股份有限公司) (the "**Company**").*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the H Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase or subscribe for any securities in the United States or in any other jurisdiction. The Offer Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "**U.S. Securities Act**") or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited as stabilizing manager (the "**Stabilizing Manager**"), its affiliates or any person acting for it, on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail in an open market for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be conducted at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last date for lodging applications under the Hong Kong Public Offering (which is Saturday, August 1, 2026). Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter. 571 of the Laws of Hong Kong).*

Potential investors should be aware that stabilizing actions cannot be taken to support the price of the Shares for longer than the stabilization period which will begin on the Listing Date and is expected to expire on the 30th day after the last day for lodging applications under the Hong Kong Public Offering (which is Saturday, August 1, 2026). After this date, no further stabilizing action may be taken, and demand for the H Shares and therefore the price of the H Shares could fall.

Potential investors of the Offer Shares should note that the Sponsor and Sole Sponsor-Overall Coordinator (for itself and on behalf of the Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed "Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination" in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, July 7, 2026).

In connection with the Global Offering, the Company is expected to grant the Over-allotment Option to the International Underwriters, exercisable by the Sole Overall Coordinator (for itself and on behalf of the International Underwriters). Pursuant to the Over-allotment Option, the International Underwriters will have the right, exercisable by the Sole Overall Coordinator (for itself and on behalf of the International Underwriters) at any time from the Listing Date until 30 days after the last day for lodging applications under the Hong Kong Public Offering (which is Saturday, August 1, 2026), to require the Company to issue and allot up to an additional 16,223,000 H Shares, representing 15% of the total number of Offer Shares, at the Offer Price, to cover over-allocations in the International Offering, if any.

Beijing Tong Ren Tang Healthcare Investment Co., Ltd.
北京同仁堂醫養投資股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	:	**108,153,500 H Shares (subject to the Over-allotment Option)**
Number of Hong Kong Offer Shares	:	**10,815,500 H Shares**
Number of International Offer Shares	:	**97,338,000 H Shares (subject to the Over-allotment Option)**
Final Offer Price	:	**HK$5.50 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015%, and Hong Kong Stock Exchange trading fee of 0.00565%**
Nominal value	:	**RMB1.00 per H Share**
Stock code	:	**2667**

Sponsor, Sole Overall Coordinator, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager

Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers

Joint Bookrunners and Joint Lead Managers

Joint Lead Managers

Beijing Tong Ren Tang Healthcare Investment Co., Ltd.
北京同仁堂醫養投資股份有限公司

ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

*Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 26, 2026 (the "**Prospectus**") issued by Beijing Tong Ren Tang Healthcare Investment Co., Ltd. (北京同仁堂醫養投資股份有限公司) (the "**Company**").*

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company information	
Stock code	2667
Stock short name	TONGRENTANGCARE
Dealings commencement date	July 7, 2026*

** See note at the end of the announcement*

Price Information	
Final Offer Price	HK$5.50
Offer Price Range	HK$5.48 – HK$6.21

Offer Shares and Share Capital	
Number of Offer Shares (assuming the Over-allotment Option is not exercised)	108,153,500
Number of Offer Shares in Hong Kong Public Offering	10,815,500
Number of Offer Shares in International Offering	97,338,000
Number of issued Shares upon Listing (assuming the Over-allotment Option is not exercised)	465,362,049

Over-allocation	
No. of Offer Shares over-allocated (Note)	5,407,500

Note: Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through deferred delivery or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website.

Proceeds	
Gross proceeds (Note)	HK$594.8 million
Less: Estimated listing expenses payable based on Final Offer Price	HK$62.4 million
Net proceeds	HK$532.4 million

Note: Gross proceeds refer to the amount to which the issuer is entitled to receive. For details of the use of proceeds, please refer to the section headed "Future Plans and Use of Proceeds" in the Prospectus. The Company will adjust the allocation of the net proceeds from the exercise of the Over-allotment Option (if any) for the purposes as set out in the section headed "Future Plans and Use of Proceeds" of the Prospectus on a pro rata basis.

ALLOTMENT RESULTS DETAILS

PUBLIC OFFER

No. of valid applications	66,390
No. of successful applications	11,293
Subscription level	251.74 times
Reallocation	N/A
No. of Offer Shares initially available under the Hong Kong Public Offering	10,815,500
No. of Offer Shares reallocated from the International Offering	0
Final no. of Offer Shares under the Hong Kong Public Offering	10,815,500
% of Offer Shares under the Hong Kong Public Offering to the Global Offering	10%

Note: For details of the final allocation of shares to the Hong Kong Public Offering, investors can refer to ***www.eipo.com.hk/eIPOAllotment*** *to perform a search by identification number or* ***www.eipo.com.hk/eIPOAllotment*** *for the full list of allottees.*

INTERNATIONAL OFFERING

No. of placees	75
Subscription Level	2.84 times
No. of Offer Shares initially available under the International Offering	97,338,000
No. of Offer Shares reallocated to the Hong Kong Public Offering	0
Final no. of Offer Shares under the International Offering	97,338,000
% of Offer Shares under the International Offering to the Global Offering	90%

The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

Cornerstone Investors

Investor [Note 1]	*No. of Offer Shares allocated*	*% of Offer Shares (assuming the Over-allotment Option is not exercised)*	*% of total issued H Shares after the Global Offering (assuming the Over-allotment Option is not exercised)*	*% of total issued Shares after the Global Offering (assuming the Over-allotment Option is not exercised)*	*Existing shareholders or their close associates*
Airport Technology Capital	39,818,000	36.82%	18.24%	8.56%	No
Aurora SF	9,010,500	8.33%	4.13%	1.94%	No
CICCFT (in connection with OTC Swaps)	5,000,000	4.62%	2.29%	1.07%	No
Total	**53,828,500**	**49.77%**	**24.66%**	**11.57%**	–

Note:

1. *For details of the Cornerstone Investors, please refer to the section headed "Cornerstone Investors" in the Prospectus.*

Allottee with consent obtained

Investor	*No. of Offer Shares allocated*	*% of Offer Shares*	*% of total issued H Shares after the Global Offering*	*% of total issued Shares after the Global Offering*	*Relationship*
Allottee with consent under paragraph 1C(1) of Appendix F1 to the Listing Rules (the "Placing Guidelines") and Chapter 4.15 of the Guide for New Listing Applicants in relation to allocation to a connected client [Note 1]					
CICCFT (in connection with OTC Swaps)	5,000,000	4.62%	2.29%	1.07%	Connected client

Note:

1. *For details of the consent under paragraph 1C(1) of the Placing Guidelines and Chapter 4.15 of the Guide for New Listing Applicants in relation to allocation to a connected client, please refer to the section headed "Others/Additional Information – Placing to allocation to a connected client with a prior consent under paragraph 1C(1) of the Placing Guidelines" in this announcement.*

LOCK-UP UNDERTAKINGS

Controlling Shareholders

Name	*Number of shares held in the Company subject to lock-up undertakings upon Listing*	*% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*% of total issued Shares after the Global Offering subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings* [Note 1]
TRT	300,000,025 Shares (including 52,930,500 H Shares)	24.25%	64.47%	July 6, 2027
TRT Medical Fund Management	1,303,079 H Shares	0.60%	0.28%	July 6, 2027
TRT Senior Care Fund	17,605,573 H Shares	8.07%	3.78%	July 6, 2027
Tongkang Fund	7,824,557 H Shares	3.58%	1.68%	July 6, 2027
Tongqing Fund	8,446,607 H Shares	3.87%	1.82%	July 6, 2027
Total	**335,179,841 Shares (including 88,110,316 H Shares)**	**40.36%**	**72.03%**	**–**

Notes:

1. *The expiry date of the lock-up period shown in the table above is pursuant to applicable PRC laws and relevant lock-up undertakings as disclosed in the Prospectus.*

2. *For illustrative purposes, this subsection lists only those members of the Controlling Shareholders who hold Shares directly in the Company. Pursuant to Rules 10.07(1) of the Listing Rules, each of the Controlling Shareholders (namely TRT, TRT Kangyang, TRT Heritage Fund Management, TRT Medical Fund Management, TRT Senior Care Fund, Tongkang Fund and Tongqing Fund) has undertaken to the Company and the Stock Exchange that, except pursuant to the Global Offering, it shall, and procure that the relevant registered holders of the Shares in which it is beneficially interested, shall, comply with the applicable lock-up requirements. For further details, please refer to the section headed "Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Undertakings Pursuant to the Listing Rules" in the Prospectus.*

Existing Shareholders (other than Controlling Shareholders) and Pre-IPO Investors

Name	*Number of shares held in the Company subject to lock-up undertakings upon Listing*	*% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*% of total issued Shares after the Global Offering subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings* [Note 1]
Mr. Zhu	7,612,833 H Shares	3.49%	1.64%	July 6, 2027
Ms. Pan	6,228,682 H Shares	2.85%	1.34%	July 6, 2027
Bozhou Yipinde	3,810,077 H Shares	1.75%	0.82%	July 6, 2027
Jining Yinling	2,592,494 H Shares	1.19%	0.56%	July 6, 2027
Bingrong Investment	1,784,622 H Shares	0.82%	0.38%	July 6, 2027
Subtotal	**22,028,708 H Shares**	**10.09%**	**4.73%**	**–**

Note:

1. The expiry date of the lock-up period shown in the table above is pursuant to applicable PRC laws and relevant lock-up undertakings as disclosed in the Prospectus.

Cornerstone Investors

Name	*Number of shares held in the Company subject to lock-up undertakings upon Listing*	*% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*% of total issued Shares after the Global Offering subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings* [Note 1]
Airport Technology Capital	39,818,000	18.24%	8.56%	February 6, 2027
Aurora SF	9,010,500	4.13%	1.94%	February 6, 2027
CICCFT (in connection with OTC Swaps)	5,000,000	2.29%	1.07%	February 6, 2027
Total	**53,828,500**	**24.66%**	**11.57%**	**–**

Note:

1. *In accordance with the relevant cornerstone investment agreements, the required lock-up ends on February 6, 2027. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date.*

   *As disclosed in the Prospectus, Aurora SF, one of the Cornerstone Investors, will hold the Offer Shares in connection with a cross border transaction placed by and fully funded by its ultimate client, Haikou Lanxin Zhitong Investment Center (Limited Partnership) (海口瀾鑫志同投資中心合夥企業(有限合夥)) ("**Haikou Lanxin**"), pursuant to which the full economic return and loss of the Offer Shares placed to Aurora SF will be ultimately borne by Haikou Lanxin according to the terms and conditions of the transactions, subject to customary fees and commissions.*

   *Haikou Lanxin is a limited partnership established in the PRC, primarily engaging in investment management and asset management activities with a focus on healthcare and consumption industries. Haikou Lanxin is owned as to (i) 0.44% by its general partner, Ms. Guo Chunyan (郭春燕), an Independent Third Party; and (ii) 99.56% by seven limited partners, none of which holds 30% or more of the partnership interest. The previous general partner of Haikou Lanxin was Mr. Zhang Liang (張亮), who also serves as the general partner of Beijing Renhuichuan Enterprise Management Development Center (Limited Partnership) (北京仁匯川企業管理發展中心(有限合夥)) ("**Beijing Renhuichuan**"), a limited partner holding 35.71% partnership interest in Tongqing Fund.*

   There are four overlapping limited partners between Haikou Lanxin and Beijing Renhuichuan, namely, Mr. Zhan Yongqing (詹永清), Mr. Yang Junyuan (楊軍元), Mr. Lin Hai (林海) and Ms. Chen Jingyu (陳京渝), who hold 21.33%, 21.33%, 21.33% and 2.22% partnership interests in Haikou Lanxin, respectively (collectively holding 66.22% partnership interest in Haikou Lanxin), and 24.69%, 19.75%, 25.93% and 2.47% partnership interests in Beijing Renhuichuan, respectively (collectively holding 72.84% partnership interest in Beijing Renhuichuan). Accordingly, through Beijing Renhuichuan's aforementioned 35.71% interest in Tongqing Fund, the same four limited partners indirectly hold a 26.0% partnership interest in Tongqing Fund. The four overlapping limited partners are independent from each other, and there are no acting-in-concert arrangements among them.

PLACEE CONCENTRATION ANALYSIS

Placees [Note 1]	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Number of H Shares held upon Listing	% of total issued Shares upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued Shares upon Listing (assuming the Over-allotment Option is fully exercised and new H Shares are issued)
Top 1	39,818,000	40.91%	38.75%	36.82%	35.06%	39,818,000	8.56%	8.46%
Top 5	74,824,000	76.87%	72.82%	69.18%	65.89%	74,824,000	16.08%	15.89%
Top 10	97,461,000	100.13%	94.86%	90.11%	85.82%	97,461,000	20.94%	20.70%
Top 25	101,994,000	104.78%	99.27%	94.30%	89.81%	101,994,000	21.92%	21.67%

Note:

1. Ranking of placees is based on the number of Shares allotted to the placees.

H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders [Note 1]	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Number of H Shares held upon Listing	% of total issued H Shares upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued H Shares upon Listing (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Number of Shares held upon Listing
Top 1	0	0.00%	0.00%	0.00%	0.00%	88,110,316	18.93%	18.72%	335,179,841
Top 5	66,524,000	68.34%	64.75%	61.51%	58.58%	154,634,316	33.23%	32.85%	401,703,841
Top 10	88,033,000	90.44%	85.68%	81.40%	77.52%	189,984,831	40.83%	40.36%	437,054,356
Top 25	101,574,000	104.35%	98.86%	93.92%	89.44%	211,713,024	45.49%	44.97%	458,782,549

Note:

1. Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

SHAREHOLDERS CONCENTRATION ANALYSIS

Shareholders [Note 1]	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued Shares upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued Shares upon Listing (assuming the Over-allotment Option is fully exercised and new H Shares are issued)
Top 1	0	0.00%	0.00%	0.00%	0.00%	88,110,316	335,179,841	72.03%	71.20%
Top 5	66,524,000	68.34%	64.75%	61.51%	58.58%	154,634,316	401,703,841	86.32%	85.33%
Top 10	88,033,000	90.44%	85.68%	81.40%	77.52%	189,984,831	437,054,356	93.92%	92.84%
Top 25	101,574,000	104.35%	98.86%	93.92%	89.44%	211,713,024	458,782,549	98.59%	97.45%

Note:

1. *Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholders upon Listing.*

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, a total of 66,390 valid applications made by the public will be conditionally allocated on the basis set out below:

BASIS OF ALLOTMENT FOR PRESS ANNOUNCEMENT

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/ BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
		POOL A	
500	31,095	2,488 out of 31,095 to receive 500 Shares	8.00%
1,000	4,943	455 out of 4,943 to receive 500 Shares	4.60%
1,500	11,161	1,242 out of 11,161 to receive 500 Shares	3.71%
2,000	1,637	210 out of 1,637 to receive 500 Shares	3.21%
2,500	1,193	179 out of 1,193 to receive 500 Shares	3.00%
3,000	716	112 out of 716 to receive 500 Shares	2.61%
3,500	378	64 out of 378 to receive 500 Shares	2.42%
4,000	340	60 out of 340 to receive 500 Shares	2.21%
4,500	261	49 out of 261 to receive 500 Shares	2.09%
5,000	3,022	574 out of 3,022 to receive 500 Shares	1.90%
6,000	351	72 out of 351 to receive 500 Shares	1.71%
7,000	1,669	374 out of 1,669 to receive 500 Shares	1.60%

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/ BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
		POOL A	
8,000	366	85 out of 366 to receive 500 Shares	1.45%
9,000	206	48 out of 206 to receive 500 Shares	1.29%
10,000	1,074	269 out of 1,074 to receive 500 Shares	1.25%
15,000	1,297	389 out of 1,297 to receive 500 Shares	1.00%
20,000	503	161 out of 503 to receive 500 Shares	0.80%
25,000	403	141 out of 403 to receive 500 Shares	0.70%
30,000	301	112 out of 301 to receive 500 Shares	0.62%
35,000	195	82 out of 195 to receive 500 Shares	0.60%
40,000	183	81 out of 183 to receive 500 Shares	0.55%
45,000	117	53 out of 117 to receive 500 Shares	0.50%
50,000	628	312 out of 628 to receive 500 Shares	0.50%
60,000	193	103 out of 193 to receive 500 Shares	0.44%
70,000	161	91 out of 161 to receive 500 Shares	0.40%
80,000	213	127 out of 213 to receive 500 Shares	0.37%
90,000	123	77 out of 123 to receive 500 Shares	0.35%
100,000	885	578 out of 885 to receive 500 Shares	0.33%
200,000	507	436 out of 507 to receive 500 Shares	0.21%
300,000	298	500 Shares	0.17%
400,000	220	500 Shares plus 62 out of 220 to receive additional 500 Shares	0.16%
500,000	200	500 Shares plus 116 out of 200 to receive additional 500 Shares	0.16%
600,000	126	500 Shares plus 101 out of 126 to receive additional 500 Shares	0.15%
700,000	95	1,000 Shares	0.14%
800,000	238	1,000 Shares plus 3 out of 238 to receive additional 500 Shares	0.13%
	65,298	Total number of Pool A successful applicants: 10,201	
		POOL B	
900,000	484	4,000 Shares	0.44%
1,000,000	333	4,000 Shares plus 230 out of 333 to receive additional 500 Shares	0.43%
2,000,000	110	6,000 Shares	0.30%
3,000,000	84	6,500 Shares plus 17 out of 84 to receive additional 500 Shares	0.22%
5,407,500	81	10,000 Shares	0.18%
	1,092	Total number of Pool B successful applicants: 1,092	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

OTHERS/ADDITIONAL INFORMATION

Placing to a connected client with prior consent under paragraph 1C(1) of the Placing Guidelines

Under the International Offering, certain Offer Shares were placed to a connected client of its connected distributor pursuant to the Placing Guidelines.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 1C(1) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to the connected client. The allocation of Offer Shares to such connected client is in compliance with all the conditions under the consent granted by the Stock Exchange. Details of the placement to connected client are set out below:

No.	Connected Distributor	Connected Client	Relationship	Whether the connected clients will hold the beneficial interests of the Offer Shares on a non-discretionary basis or discretionary basis for independent third parties	Number of Offer Shares to be allocated to the Connected Client	Approximate percentage of total number of Offer Shares under the Global Offering (assuming the Over-allotment Option is not exercised)	Approximate percentage of total issued Shares after the Global Offering (assuming the Over-allotment Option is not exercised)
1.	China International Capital Corporation Hong Kong Securities Limited ("**CICC HKS**")	CICCFT	CICCFT is a member of the same group of companies as CICCHKS.	Non-discretionary basis	5,000,000	4.62%	1.07%

Note:

*(1) CICCFT and China International Capital Corporation Limited have entered into a series of cross border over-the-counter swap transactions (collectively, the "**CICCFT OTC Swaps**") with each other, and with Guangdong Hengqin Guangxin Meihao Private Fund Management Co., Ltd. (廣東橫琴廣鑫美好私募基金管理有限公司) ("**Guangxinmeihao Fund**") acting in its capacity as fund manager for and on behalf of Meihao Planck No. 1 Private Securities Investment Fund (美好普朗克一號私募證券投資基金) (the "**Planck No. 1 Fund**" or "**CICCFT Ultimate Client**"), pursuant to which CICCFT will hold the Offer Shares on a nondiscretionary basis to hedge the CICCFT OTC Swaps while the economic risks and returns of the underlying Offer Shares are passed to the CICCFT Ultimate Client, subject to customary fees and commissions. The CICCFT OTC Swaps will be fully funded by the CICCFT Ultimate Client.*

To the best of CICCFT's knowledge having made all reasonable inquiries, Guangxinmeihao Fund and its ultimate beneficial owner are independent third parties of CICCFT, CICCHKS and the companies which are members of the same group of CICCHKS.

To the best of CICCFT's knowledge having made all reasonable inquiries, the CICCFT Ultimate Client is an independent third party of CICCFT, CICCHKS and the companies which are members of the same group of CICCHKS.

*The Planck No. 1 Fund is established as a contractual fund without a separate legal personality. Guangxinmeihao Fund, which is ultimately controlled by Mr. Luo Liang (羅亮), is the fund manager of Planck No. 1 Fund, China Merchants Securities Co., Ltd. (招商證券股份有限公司) is the fund trustee, and Ms. Li Bo (李博) and Mr. Xu Chen (徐琛) are the beneficiaries, all of which are independent third parties of the Group and the Controlling Shareholders. The Group became acquainted with Ms. Li Bo and Mr. Xu Chen through introduction by suppliers of the Group, Beijing Wantailike Pharmaceutical Co., Ltd. (北京萬泰利克藥業有限公司) ("**Beijing Wantailike**") and Zhenxing Baicao (Beijing) Pharmaceutical Co., Ltd. (振興百草(北京)藥業有限責任公司) ("**Zhenxing Baicao**"), respectively, not through introduction by CICC. Beijing Wantailike and Zhenxing Baicao were not the five largest suppliers of the Group during the Track Record Period. For the years ended December 31, 2023, 2024 and 2025, the Group's purchase amount from Beijing Wantailike accounted for 0.2%, 0.3% and 1.1% of its total purchase for the same periods, respectively. For the years ended December 31, 2023, 2024 and 2025, the Group's purchase amount from Zhenxing Baicao accounted for 1.3%, 1.8% and 2.2% of its total purchases for the same periods, respectively, and the revenue contribution of Zhenxing Baicao accounted for less than 1% of its total revenue for the same periods, respectively.*

DISCLAIMERS

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*
*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase or subscribe for any securities in the United States or in any other jurisdiction. The Offer Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "**U.S. Securities Act**") or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States.*
The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.
This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus dated June 26, 2026 issued by the Company for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.
**Potential investors of the Offer Shares should note that the Sponsor and Sole Sponsor-Overall Coordinator (for itself and on behalf of the Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed "Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination" in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, July 7, 2026).*

PUBLIC FLOAT AND FREE FLOAT

Immediately after the completion of the Global Offering before any exercise of the Over-allotment Option, 116,340,693 H Shares, the total number of the H Shares held by the public represents approximately 25.00% of the total issued share capital of the Company, which is at least 25% as required under Rule 19A.13A of the Listing Rules, will be counted towards the public float upon the Listing. Therefore, the Company will be able to meet the minimum public float requirement under Rule 19A.13A(1) of the Listing Rules.

Each of the Cornerstone Investors has agreed to a lock-up period of seven months following the Listing Date. As such, H Shares held by the Cornerstone Investors upon the Listing shall not be counted towards the free float of the Shares of the Company at the time of Listing. Based on the final Offer Price of HK$5.50 per H Share, the Company confirms the free float requirement under Rule 19A.13C(1)(a) of the Listing Rules.

The Directors confirm that, immediately following completion of the Global Offering (before any exercise of the Over-allotment Option): (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder under the Listing Rules immediately after the Global Offering; (iii) the three largest public shareholders of the Company do not hold more than 50% of the Shares in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, July 7, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed "Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination" in the Prospectus has not been exercised. Investors who trade H Shares prior to the receipt of H Share certificates or the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Tuesday, July 7, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, July 7, 2026 (Hong Kong time). The H Shares will be traded in board lots of 500 H Shares each. The stock code of the H Shares will be 2667.

By order of the Board
Beijing Tong Ren Tang Healthcare Investment Co., Ltd.
Mr. Rao Zuhai
Chairman of the Board and Executive Director

Hong Kong, July 6, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Rao Zuhai, Mr. Lu Yan and Ms. Gui Shan as executive directors; (ii) Mr. Zhu Feng, Mr. Sun Kai and Ms. Xing Qian as non-executive directors; and (iii) Mr. Yim, Chi Hung Henry, Mr. Zhang Xiang and Mr. Gao Yanbin as independent non-executive directors.